48 Quick summary: A large scale data analysis from Peking University People’s Hospital has revealed that radical surgery to remove the kidney and surrounding tissues provides superior overall and cancer specific survival compared with kidney sparing procedures for patients with rare urethral urinary tract cancer. This statistical matching study showed that the survival advantage of radical surgery is particularly pronounced in patients with localized disease, larger tumours, or those who did not undergo lymph node dissection. These findings carry critical implications for international healthcare practice and public policy by reinforcing the need for highly individualised surgical planning, helping clinicians navigate the complex clinical trade-offs between aggressive oncologic control and long-term kidney preservation to optimize patient survival and well-being. Urethral cancer is rare, leaving patients and doctors facing a difficult surgical choice. Radical surge, the total removal of the kidney, ureter, and part of the bladder, offers the strongest defense against the cancer. In contrast, kidney-sparing surgery preserves vital organ function, leaving clinicians to navigate the delicate trade-off between absolute disease control and long-term quality of life. A major population-based study from researchers at Peking University People’s Hospital has shed new light on this issue. The team analysed data from the US Surveillance, Epidemiology, and End Results (SEER) database, including 2841 patients diagnosed with primary urethral urothelial carcinoma between 2000 and 2021. To address differences between the treatment groups, they applied propensity score matching, creating a balanced cohort of 1646 patients for more reliable comparison. “In urethral cancer, whether to preserve the organ or eradicate the tumour has always been a controversy,” said the study’s lead author, Yuxuan Song, a urologic surgeon at the Department of Urology at Peking. The research, published in Medicine Plus, revealed important differences after statistical matching. Before matching, overall survival and cancer-specific survival did not differ significantly between kidney-sparing surgery and radical nephroureterectomy. After matching, however, radical nephroureterectomy was associated with better overall survival and cancer-specific survival than kidney-sparing surgery. Exploratory subgroup analyses indicated that this survival advantage was particularly pronounced across several specific categories. These included patients with T1/N0/M0 disease, individuals who did not undergo lymph node dissection, and those diagnosed in more recent years. The association was also notably stronger for patients with tumours measuring between 5 cm and 10 cm. Urethral urothelial carcinoma forms part of upper tract urothelial carcinoma, which is less common than bladder cancer but often more aggressive. Data indicates that survival for ureter cancer can be around 46% at 5 years in some population data, with outcomes varying significantly by stage and grade. Radical nephroureterectomy has traditionally served as the standard treatment to minimise the risk of recurrence within the urinary tract. However, kidney-sparing approaches have gained considerable traction, particularly for patients with existing renal impairment or those facing a heightened risk of chronic kidney disease should they lose the organ. Song emphasised that these findings should be interpreted as associations from a retrospective registry-based study, not as definitive evidence that one operation is universally superior. Because kidney-sparing surgery includes several different procedures and the SEER database lacks detailed information on renal function, recurrence, operative factors, and quality of life, further studies are needed to refine patient selection. The study provides population-level evidence to support more personalised treatment planning. Rather than applying a blanket surgical strategy to all patients, the findings highlight the importance of weighing tumour stage and size, lymph node dissection status, and patient-specific factors when balancing kidney preservation against oncologic control. Song is a researcher focusing on novel diagnosis and prognosis of urological tumours by integrating multi-omics data, organoids, and large language models. He and colleagues contribute valuable data to ongoing discussions in urological oncology with this study. Experts in the field note that treatment choices for upper tract urothelial cancers must account for individual patient risks, including potential impacts on kidney function and overall quality of life. While radical approaches may offer stronger cancer control in certain matched cohorts, kidney-sparing options remain important for selected low-risk cases where close surveillance is feasible. This large-scale analysis adds to the evidence base for clinicians in the UK and internationally when counselling patients about surgical options for urethral urothelial carcinoma. It underscores the need for continued research, including prospective studies that capture more granular data on functional outcomes and long-term quality of life. The research team hopes their work will encourage more individualised decision-making, helping patients and doctors navigate the trade-offs between cancer control and organ preservation more effectively. As diagnostic and surgical techniques advance, such data-driven insights become increasingly vital for improving outcomes in this challenging disease.